Challenges in the Development of Novel Cardiovascular Therapies-Reference-Cited by-同舟云学术

Challenges in the Development of Novel Cardiovascular Therapies

Published:2017-06-23 Issue:2 Volume:102 Page:194-196
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Hwang TJ¹,Kesselheim AS¹

Affiliation:

1. Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine; Brigham and Women's Hospital and Harvard Medical School; Boston Massachusetts USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.703/fullpdf

Reference5 articles.

1. Temporal trends and factors associated with cardiovascular drug development, 1990 to 2012;Hwang;J. Am. Coll. Cardiol. Basic Trans. Sci.,2016

2. Angiotensin-neprilysin inhibition versus enalapril in heart failure;McMurray;N. Engl. J. Med.,2014

3. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial;Nicholls;JAMA,2014

4. Cardiovascular drug development: is it dead or just hibernating?;Fordyce;J. Am. Coll. Cardiol.,2015

5. The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs;Kesselheim;Health Affairs,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular cardiopharmacology and Therapeutics-I;Biochemical and Molecular Pharmacology in Drug Discovery;2024

2. Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis;Frontiers in Cardiovascular Medicine;2022-03-11

3. Nanovesicles for the delivery of cardiovascular drugs;Applications of Nanovesicular Drug Delivery;2022

4. Multicellular Human Cardiac Organoids Transcriptomically Model Distinct Tissue-Level Features of Adult Myocardium;International Journal of Molecular Sciences;2021-08-06

5. Nrf2 activator-encapsulating polymeric nanoparticles and LDL-like nanoparticles target atherosclerotic plaque;2020-06-11